CD47 and cancer: Interestingly, the use of anti‐CD47 monoclonal antibody (mAb), in order to disrupt this checkpoint interaction between cancer cells and TAMs (also known as ‘don't eat me’ signal, DEMs), showed promising clinical activity in pretreated NHL, thanks to the increase in phagocytosis mediated by TAMs.11